HepaRegeniX
Developing liver diseases treatment
HepaRegeniX GmbH is a clinical stage company developing novel therapies for the treatment of acute and chronic liver diseases. Since its start in 2017, HepaRegeniX has successfully discovered and developed several drug candidates for the treatment of acute and chronic liver diseases based on a novel proprietary molecular target Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4).
Visit website: https://www.heparegenix.com/
Details last updated 08-Apr-2024
HepaRegeniX News
A new drug targeting liver cell growth shows excellent safety results in humans
HepaRegeniX GmbH - 15-Mar-2024
This could change the way we treat liver cancer and address transplant organ shortages
Read more...